Similar articles

• [The use of thymostimulin in lymphoma and myeloma patients].

  Cánovas Fernández A, Alonso Alonso J, González de Zárate P, García Masdevall MD, Riñón Martínez-Gallo M, Aguirre Errasti C. Cánovas Fernández A, et al. An Med Interna. 1991 Feb;8(2):69-73. An Med Interna. 1991. PMID: 1893006 Clinical Trial. Spanish.
• [Our experience in the treatment of Hodgkin's disease and other reticulopathies with Ro4-6467 (Natulan)].

  Arroyo de la Fuente F, Lasheras Garde J, Triginer Boixeda J. Arroyo de la Fuente F, et al. Sangre (Barc). 1966;11(3):265-70. Sangre (Barc). 1966. PMID: 6012465 Spanish. No abstract available.
• [Personal experience on the chemotherapy of leukemias and hematosarcomas].

  Mathé G, Schneider M, Schwarzenberg L, Cattan A, Amiel JL, Schlumberger JR. Mathé G, et al. Acta Genet Med Gemellol (Roma). 1968 Jan;17(1):245-54. Acta Genet Med Gemellol (Roma). 1968. PMID: 4874537 French. No abstract available.
• [Natulan (experimental and clinical data on its antitumor effect)].

  Brodskaia NA. Brodskaia NA. Vopr Onkol. 1972;18(11):101-9. Vopr Onkol. 1972. PMID: 4566561 Review. Russian. No abstract available.
• Review. Clinical pharmacokinetics of bortezomib.

  Levêque D, Carvalho MC, Maloisel F. Levêque D, et al. In Vivo. 2007 Mar-Apr;21(2):273-8. In Vivo. 2007. PMID: 17436576 Review.